Denemek ALTIN - Özgür

Research misconduct ...can delay meaningful and reliable discoveries

Express Pharma

|

October 2025

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

- By Viveka Roychowdhury

Research misconduct ...can delay meaningful and reliable discoveries

In terms of peer review fraud, research misconduct, how large is the problem, globally and specifically for pharma/life science research papers being published out of India?

In recent years, we have seen increased reporting in scholarly and traditional news on instances of suspected research misconduct and publication integrity violations. This has ranged from investigations into individual authors or researcher groups to large-scale retraction of many thousands of articles. The observed increase in the number of articles being retracted can be attributed, in part, to improvements in detection systems by publishers; however, it may also reflect a change in the rate of research or publication misconduct.

There are no completely accurate rates of research misconduct or peer review fraud available, in part because of the existence of as yet undiscovered misconduct and the high professional cost of admitting to misconduct. Some attempts to quantify this exist, for example, a 2016 study found that just under 4 per cent of screened published papers contained problematic images [1].

Another study looking at nucleotide sequences found that 713 out of >3400 screened articles contained incorrectly described nucleotide sequences [2]. Even less certain is the prevalence of misconduct in unpublished works. An analysis on paper mills from the Committee on Publication Ethics (COPE) and the STM Association [3] found that publishers reported that between 2-46 per cent of the submissions to a journal can be suspected of having paper mill involvement.

Express Pharma'den DAHA FAZLA HİKAYE

Express Pharma

Express Pharma

Speed and flexibility play a critical role in how we compete with larger global players

Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Vizag rising: Shaping India's pharma future

At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth

time to read

9 mins

January 2026

Express Pharma

Express Pharma

Future of pharma: Trends, challenges & AI

Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies

time to read

2 mins

January 2026

Express Pharma

Express Pharma

Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments

When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.

time to read

1 mins

January 2026

Express Pharma

Express Pharma

Can Indian biosimilars and generics restate accessibility in global underserved markets?

Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare

time to read

3 mins

January 2026

Express Pharma

Express Pharma

The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers

As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Results win customers. Leadership discipline keeps them

Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.

time to read

3 mins

January 2026

Express Pharma

Express Pharma

INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF

India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge

time to read

8 mins

January 2026

Express Pharma

Express Pharma

PRUV® -The original Sodium Stearyl Fumarate

JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago

time to read

5 mins

January 2026

Express Pharma

Express Pharma

Odisha's pharma pitch

The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury

time to read

5 mins

January 2026

Listen

Translate

Share

-
+

Change font size